Turnstone Biologics Corp.

TSBX

US90042W1009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.05 ^USD	+6.27%		+12.13%	+19.84%

Apr. 16	Turnstone Biologics Corp. Announces Board Changes	CI
Mar. 21	Turnstone Biologics Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Turnstone Biologics Corp. Announces Demise of P. Joseph Campisi, Jr., Esq, Chief Legal Officer

February 20, 2024 at 05:00 pm EST

Turnstone Biologics Corp. announced that P. Joseph Campisi, Jr., Esq, the company?s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.

Latest news about Turnstone Biologics Corp.

Turnstone Biologics Corp. Announces Board Changes	Apr. 16	CI
Turnstone Biologics Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
Turnstone Biologics Corp. Announces Demise of P. Joseph Campisi, Jr., Esq, Chief Legal Officer	Feb. 20	CI
Certain Common Stock of Turnstone Biologics Corp. are subject to a Lock-Up Agreement Ending on 17-JAN-2024.	Jan. 16	CI
Certain Stock Options of Turnstone Biologics Corp. are subject to a Lock-Up Agreement Ending on 17-JAN-2024.	Jan. 16	CI
Turnstone Biologics Falls 11% in Premarket Activity Tuesday After Surging 42% in Previous Regular Trading Session	Dec. 05	MT
Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Top Premarket Gainers	Nov. 03	MT
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors At the 2023 Society for Immunotherapy of Cancer Annual Meeting	Nov. 03	CI
Turnstone Biologics Corp.(NasdaqGM:TSBX) added to S&P TMI Index	23-09-18	CI
BofA Securities Initiates Turnstone Biologics at Buy	23-08-15	MT
Piper Sandler Starts Turnstone Biologics at Overweight, $20 Price Target	23-08-15	MT
Insider Buy: Turnstone Biologics	23-07-27	MT
Insider Buy: Turnstone Biologics	23-07-24	MT
Turnstone Biologics Corp.(NasdaqGM:TSBX) added to NASDAQ Composite Index	23-07-24	CI
Turnstone Biologics Corp. has completed an IPO in the amount of $80.000004 million.	23-07-20	CI
Turnstone Biologics Corp. has filed an IPO in the amount of $86.25 million.	23-06-12	CI

Chart Turnstone Biologics Corp.

Duration

Period

More charts

Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patientâs tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.05 USD

Average target price

13 USD

Spread / Average Target

+326.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TURNSTONE BIOLOGICS CORP.	+19.84%	70.54M
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals